The National Institutes of Health (NIH) is offering a grant to support research on the etiology, diagnosis, pathophysiology, and manifestations of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in diverse groups and across the lifespan. Emphasis is on investigating environmental and biological risk factors, determinants of heterogeneity, and common mechanisms influencing affected body systems. Interdisciplinary projects focusing on biomarkers, pathophysiological responses, and innovative research approaches are encouraged. The R21 grant is designed for high-impact research, including generating pilot data, high-risk experiments, and new technology feasibility studies. Proposals with groundbreaking potential are sought to enhance ME/CFS understanding and improve patient outcomes. Closing date for applications is May 07, 2023.
Opportunity ID: 326295
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-20-168 |
| Funding Opportunity Title: | Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Environment Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.113 — Environmental Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 13, 2020 |
| Last Updated Date: | Apr 13, 2020 |
| Original Closing Date for Applications: | May 07, 2023 |
| Current Closing Date for Applications: | May 07, 2023 |
| Archive Date: | Jun 12, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $200,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Private institutions of higher education Special district governments State governments Independent school districts Small businesses Public and State controlled institutions of higher education County governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Proposals submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-20-168.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 326295 Full Announcement-PAR-20-168 -> PAR-20-168-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00260998 | May 16, 2020 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00270275 | Nov 16, 2021 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278107 | Nov 08, 2022 | May 07, 2023 | View |
Package 1
Mandatory forms
326295 RR_SF424_2_0-2.0.pdf
326295 PHS398_CoverPageSupplement_5_0-5.0.pdf
326295 RR_OtherProjectInfo_1_4-1.4.pdf
326295 PerformanceSite_2_0-2.0.pdf
326295 RR_KeyPersonExpanded_2_0-2.0.pdf
326295 PHS398_ResearchPlan_4_0-4.0.pdf
326295 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
326295 RR_Budget_1_4-1.4.pdf
326295 RR_SubawardBudget30_1_4-1.4.pdf
326295 PHS398_ModularBudget_1_2-1.2.pdf
326295 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
326295 RR_SF424_5_0-5.0.pdf
326295 PHS398_CoverPageSupplement_5_0-5.0.pdf
326295 RR_OtherProjectInfo_1_4-1.4.pdf
326295 PerformanceSite_4_0-4.0.pdf
326295 RR_KeyPersonExpanded_4_0-4.0.pdf
326295 PHS398_ResearchPlan_4_0-4.0.pdf
326295 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
326295 RR_Budget_3_0-3.0.pdf
326295 RR_SubawardBudget30_3_0-3.0.pdf
326295 PHS398_ModularBudget_1_2-1.2.pdf
326295 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
326295 RR_SF424_5_0-5.0.pdf
326295 PHS398_CoverPageSupplement_5_0-5.0.pdf
326295 RR_OtherProjectInfo_1_4-1.4.pdf
326295 PerformanceSite_4_0-4.0.pdf
326295 RR_KeyPersonExpanded_4_0-4.0.pdf
326295 PHS398_ResearchPlan_5_0-5.0.pdf
326295 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
326295 RR_Budget_3_0-3.0.pdf
326295 RR_SubawardBudget30_3_0-3.0.pdf
326295 PHS398_ModularBudget_1_2-1.2.pdf
326295 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
